08:14 AM EDT, 09/10/2024 (MT Newswires) -- Viridian Therapeutics ( VRDN ) said Tuesday that a phase 3 clinical trial of VRDN-001 or veligrotug, a potential treatment of active thyroid eye disease, met all primary and secondary endpoints at 15 weeks after five infusions.

Overall, 67% of patients receiving the intravenously delivered drug achieved proptosis response and a 2-point reduction at least in clinical activity score from baseline, compared with 5% of patients given a placebo, the company said.

Viridian also said veligrotug, an anti-insulin-like growth factor-1 receptor antibody, was generally well-tolerated, with no serious adverse events.

Shares of the company were up more than 14% in Tuesday's premarket activity.

Price: 16.27, Change: +2.08, Percent Change: +14.66